$35? Based on “conservative” estimates of sales? Lol, cmon. Stop talking so much book.
The float will be 400 mil before long. Already 375 mil fully diluted. So you think a roughy $14B market cap is conservative now? Totally disagree.
Based on a very limited pipeline, 2:1 price to sales, your figure assumes $7B annual sales as an average, for a span of at least 10 years. Lipitor’s peak year (not average) annual worldwide sales at about 80% market saturation, similar pricing to Vascepa (considering margins), and much much wider demographic was $12.8B. So no, I think you’re far off. Actually at $20 it’s overpriced even in optimistic scenarios (like generics being staved off for full patent term, which isn’t likely).
No I think the only way you get to those numbers is if AMRN can manage to sock away a few billion before their market share disappears and then acquire a small cap with promising candidates. Spend $500mm - $1B on the acquisition and $2B-$3B finishing trials and marketing. But all that’s no guarantee either, and they’ll have to compete with BP for the best picks.
Jmo